Description

Simple

A medication used in emergencies to increase blood pressure.

Clinical

A peptide hormone used to increase blood pressure in patients with vasodilatory shock who are resistant to fluid and catecholamine therapy.

Overview

Antidiuretic hormone, also known as vasopressin, is a nine amino acid peptide secreted from the posterior pituitary. Antidiuretic hormone binds to receptors in the distal or collecting tubules of the kidney and promotes reabsorbtion of water back into the circulation

Pharmacology

Indication

For the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding

Pharmacodynamic

Vasopressin is an antidiuretic hormone indicated for the prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows, and in diabetes insipidus. Vasopressin can cause contraction of smooth muscle of the gastrointestinal tract and of... Read more

Mechanism of action

Vasopressin acts on three different receptors, vasopressin receptor V1a (which initiates vasoconstriction, liver gluconeogenesis, platelet aggregation and release of factor VIII), vasopressin receptor V1b (which mediates corticotrophin secretion from the pituitary) and vasopressin receptor V2 which... Read more

Absorption

Information currently not available.

Protein binding

1%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

10-20 minutes

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

  • Avoid alcohol.

Interactions

Type in a drug name to check for interaction with Vasopressin
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Ardeparin
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Ardeparin.
Bemiparin
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Bemiparin.
Carbamazepine
The risk or severity of water intoxication can be increased when Carbamazepine is combined with Vasopressin.
Certoparin
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Certoparin.
Dalteparin
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Dalteparin.
Danaparoid
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Danaparoid.
Enoxaparin
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Enoxaparin.
Heparin
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Heparin.
Levothyroxine
Levothyroxine may increase the vasoconstricting activities of Vasopressin.
Lidocaine
The risk or severity of hypertension can be increased when Vasopressin is combined with Lidocaine.
Liothyronine
Liothyronine may increase the vasoconstricting activities of Vasopressin.
Liotrix
Liotrix may increase the vasoconstricting activities of Vasopressin.
Lithium carbonate
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium carbonate.
Lithium cation
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium cation.
Lithium citrate
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium citrate.
Lithium hydroxide
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Lithium hydroxide.
Nadroparin
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Nadroparin.
Norepinephrine
The risk or severity of adverse effects can be increased when Norepinephrine is combined with Vasopressin.
Parnaparin
The therapeutic efficacy of Vasopressin can be decreased when used in combination with Parnaparin.
Patent Blue
The risk or severity of hypotension can be increased when Patent Blue is combined with Vasopressin.
5 References
  1. 1 . Bielsky IF, Hu SB, Szegda KL, Westphal H, Young LJ: Profound impairment in social recognition and reduction in anxiety-like behavior in vasopressin V1a receptor knockout mice. Neuropsychopharmacology. 2004 Mar;29(3):483-93.PubMed: 14647484
  2. 2 . Wersinger SR, Caldwell HK, Martinez L, Gold P, Hu SB, Young WS 3rd: Vasopressin 1a receptor knockout mice have a subtle olfactory deficit but normal aggression. Genes Brain Behav. 2007 Aug;6(6):540-51. Epub 2006 Nov 3.PubMed: 17083331
  3. 3 . Lolait SJ, Stewart LQ, Jessop DS, Young WS 3rd, O'Carroll AM: The hypothalamic-pituitary-adrenal axis response to stress in mice lacking functional vasopressin V1b receptors. Endocrinology. 2007 Feb;148(2):849-56. Epub 2006 Nov 22.PubMed: 17122081
  4. 4 . Wersinger SR, Kelliher KR, Zufall F, Lolait SJ, O'Carroll AM, Young WS 3rd: Social motivation is reduced in vasopressin 1b receptor null mice despite normal performance in an olfactory discrimination task. Horm Behav. 2004 Dec;46(5):638-45.PubMed: 15555506
  5. 5 . Kanwar S, Woodman RC, Poon MC, Murohara T, Lefer AM, Davenpeck KL, Kubes P: Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules. Blood. 1995 Oct 1;86(7):2760-6.PubMed: 7545469